ofranergene obadenovec
AXP000145.1 · Viral vector gene therapy
- Platform
- adenovirus (Ad5, non-replicating, PPE-1-3x endothelial promoter)
- Originator
- Vascular Biogenics (VBL Therapeutics)
- Sponsor
- Notable Labs
Names
| Name | Type | Source |
|---|---|---|
| ofranergene obadenovec | preferred name, INN | curator, ncit |
| Ofra-Vec | brand | press |
| VB-111 | code | ncit |
| GT-111 ambiguous | former code | ncit |
Virus
- Role
- In vivo gene transfer
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5
- Replication
- non replicating
- Modifications
- non-replicating Ad5; modified murine PPE-1 promoter with three endothelium-specific enhancer copies and a hypoxia-responsive element
- Transgenes
- Fas-chimera (TNFRSF1A-FAS fusion)
- Route
- intravenous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C71539
- FDA UNII
- 5Q5PRH05GI
Approvals
No regulatory approval recorded.
Clinical trials (7)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04166383 | VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) | Terminated | Phase 2 | 2020-08-09 | 2022-04-12 | 14 | Colorectal Cancer With Hepatic Metastases; Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumors; Metastatic Colorectal Cancer |
| NCT04406272 | VB-111 in Surgically Accessible Recurrent/Progressive GBM | Terminated | Phase 2 | 2020-08-01 | 2024-08-01 | 15 | Glioblastoma; Recurrent Glioblastoma |
| NCT03398655 | A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) | Completed | Phase 3 | 2017-12-19 | 2022-07-19 | 408 | Recurrent Platinum Resistant Ovarian Cancer |
| NCT02511405 | A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) | Completed | Phase 3 | 2015-08 | 2017-11-03 | 252 | Glioblastoma |
| NCT01260506 | Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme | Completed | Phase 1/2 | 2010-12 | 2015-07-23 | 75 | Glioblastoma Multiforme |
| NCT01229865 | Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer | Completed | Phase 2 | 2010-12 | 2014-10 | 29 | Differential Thyroid Cancer |
| NCT00559117 | A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer | Unknown | Phase 1 | 2007-11 | 2015-06 | 48 | Advanced and/or Metastatic Solid Organ Cancer |
Unconfirmed matches (1)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT01711970 | A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer | Completed | Phase 1/2 | 2012-11 | 2017-05-03 | 38 | Platinum Resistant Ovarian Cancer | name in title: VB-111 |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 37906726 | Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018). | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024 | cited by trial NCT03398655 |
| PMID 38184304 | VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial. | Journal for immunotherapy of cancer | 2024 | cited by trial NCT04166383 |
| PMID 37540556 | Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2023 | cited by trial NCT02511405 |
| PMID 33637348 | Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer. | Gynecologic oncology | 2021 | cited by trial NCT03398655 |
| PMID 31844886 | Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study. | Neuro-oncology | 2020 | name in title: VB-111 |
| PMID 31844890 | A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). | Neuro-oncology | 2020 | cited by trial NCT02511405 |
| PMID 32265057 | Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect. | Gynecologic oncology | 2020 | name in title: ofranergene obadenovec |
| PMID 23589178 | Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2013 | name in title: VB-111 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 34377989 | Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma. | Neuro-oncology advances | 2021 | name in title: VB-111 |
| PMID 26108658 | VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme. | Journal of neuro-oncology | 2015 | name in title: VB-111 |
| PMID 21961496 | VB-111 for cancer. | Expert opinion on biological therapy | 2011 | name in title: VB-111 |
| PMID 22701765 | Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models. | Genes & cancer | 2011 | name in title: VB-111 |
Unconfirmed matches (2)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 34973444 | Efficacy and Safety of Bevacizumab Combined with Other Therapeutic Regimens for Treatment of Recurrent Glioblastoma: A Network Meta-analysis. | World neurosurgery | 2022 | name in abstract: VB-111 |
| PMID 20506053 | American association for cancer research - 101st annual meeting - investigating new therapeutic candidates: part 2. | IDrugs : the investigational drugs journal | 2010 | name in abstract: VB-111 |
NIH grants
No confirmed grants yet.
Unconfirmed matches (1)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| ZIABC011343 | Clinical protocols for the treatment of gastrointestinal cancer | DIVISION OF BASIC SCIENCES - NCI | GRETEN, TIM | 2019–2023 | name in abstract: VB-111 |
Notes
VB-111: non-replicating Ad5 in which a modified murine pre-proendothelin-1 promoter (PPE-1-3x, with a hypoxia-responsive element) drives a Fas-chimera transgene (TNFR1 extracellular and transmembrane domains fused to the Fas intracellular death domain), to kill angiogenic tumour endothelium. Given intravenously. Phase 3 OVAL in platinum-resistant ovarian cancer did not show benefit; earlier phase 3 in recurrent glioblastoma (GLOBE) also failed.
How to cite
ofranergene obadenovec (AXP000145.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000145.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.